oral GCN2 kinase inhibitor

TGI in LL2 syngeneic mouse model

SAR opt. from literature starting point

J. Med. Chem.

RAPT Therapeutics, South San Francisco, CA

Compound 39 chemical structure oral GCN2 kinase inhibitor - RAPT Therapeutics, South San Francisco, CA

Context. “Compound 39” (RAPT Therapeutics) is a general control nonderepressible 2 (GCN2) protein kinase inhibitor. As the master regulator of the integrated stress response triggered by cellular stress in…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: